Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2024
0mins
Source: PRnewswire
Reverse Stock Split Announcement: Kintara Therapeutics has approved a reverse stock split of its common stock at a ratio of 1-for-35, effective October 18, 2024, following the merger with TuHURA Biosciences, Inc. This will reduce the number of outstanding shares from approximately 55.6 million to about 1.6 million.
Company Transition and Focus: After the merger, Kintara will operate under the new name TuHURA Biosciences, focusing on developing innovative cancer therapies, including a personalized cancer vaccine candidate and novel antibody drug conjugates targeting immune suppression in tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
